{"disease":{"id":"dm1","name":"dm1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07385443","title":"The Spanish National Registry for Myotonic Dystrophy Type 1","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Fundació Institut Germans Trias i Pujol","has_results":false},{"nct_id":"NCT07505342","title":"Remote Assessments and Genetic Determinants of Myotonic Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT03981575","title":"Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT04907162","title":"Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT03589677","title":"Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"IRCCS San Camillo, Venezia, Italy","has_results":false},{"nct_id":"NCT06185764","title":"A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT06926621","title":"A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":44,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT05072288","title":"A Remote Physical Activity Program in the Population Suffering from Type 1 Myotonic Dystrophy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Université du Québec à Chicoutimi","has_results":false},{"nct_id":"NCT05027269","title":"Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false},{"nct_id":"NCT05479981","title":"Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false},{"nct_id":"NCT04835298","title":"Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT03959189","title":"Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Expansion Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05560438","title":"Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1","phase":"NA","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"University of Oslo","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}